BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-851@pharmaconomics
DTSTAMP:20260707T010111Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:SLS Phase 2 — SLS009 (estimated date)
DESCRIPTION:Phase 2 trial results for SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-202605128xkexhibit991.htm\n\nTrack it: https://www.pharmaconomics.com/e/851
URL:https://www.pharmaconomics.com/e/851
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SLS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR